Cargando…
Characteristics of new adult users of mepolizumab with asthma in the USA
BACKGROUND: In the USA, over 25 million people have asthma; 5%–10% of cases are severe. Mepolizumab (Nucala) is an interleukin-5 antagonist monoclonal antibody; it was approved by the FDA in 2015 as add-on maintenance treatment of severe asthma for patients aged ≥12 years with an eosinophilic phenot...
Autores principales: | Wu, Ann Chen, McMahon, Pamela M, Welch, Emily, McMahill-Walraven, Cheryl N, Jamal-Allial, Aziza, Gallagher, Mia, Zhang, Tancy, Draper, Christine, Kline, Anne Marie, Koerner, Leslie, Brown, Jeffrey S, Van Dyke, Melissa K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572414/ https://www.ncbi.nlm.nih.gov/pubmed/34732517 http://dx.doi.org/10.1136/bmjresp-2021-001003 |
Ejemplares similares
-
Patient characteristics, pain treatment patterns, and incidence of total joint replacement in a US population with osteoarthritis
por: Shinde, Mayura, et al.
Publicado: (2022) -
Grandmaternal smoking, asthma and lung function in the offspring: the Lifelines cohort study
por: Mahon, Gillian M, et al.
Publicado: (2021) -
Reslizumab as add-on therapy in patients with refractory asthma
por: Virchow, J Christian, et al.
Publicado: (2020) -
Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone
por: Bateman, Eric D, et al.
Publicado: (2014) -
Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β(2) agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trial
por: Busse, William W, et al.
Publicado: (2013)